Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Apex Healthcare Berhad is a leading distributor of pharmaceutical and medical products in Malaysia, with a significant presence in Southeast Asia. The company benefits from a diversified portfolio of over 10,000 products, including prescription medications, over-the-counter drugs, and medical devices, positioning it well against competitors in the region.
Apex Healthcare generates revenue primarily through the distribution of pharmaceutical products to hospitals, clinics, and pharmacies, leveraging strong relationships with healthcare providers. The company has pricing power due to its established brand reputation and extensive product range, which allows it to maintain stable margins despite competitive pressures.
Changes in healthcare regulations affecting pharmaceutical pricing and distribution
Growth in the Malaysian healthcare market driven by an aging population
New product launches and partnerships with international pharmaceutical firms
Fluctuations in raw material costs impacting gross margins
Regulatory changes in the pharmaceutical industry that could affect pricing and market access
Technological advancements in healthcare that may disrupt traditional distribution models
Increased competition from local and international distributors
Potential market entry of e-commerce platforms in pharmaceutical sales
Low liquidity due to negative free cash flow (-$0.0B) could limit operational flexibility
Dependence on a few key suppliers for pharmaceutical products
moderate - The healthcare sector is generally resilient during economic downturns, but Apex's revenue growth can be impacted by overall consumer spending and healthcare budgets.
Interest rates affect Apex's financing costs for inventory and expansion. Higher rates could dampen consumer spending on healthcare products, impacting revenue growth.
minimal - Apex has a low debt-to-equity ratio (0.06), indicating limited reliance on external financing.
value - The stock's low debt levels and stable cash flows appeal to value investors seeking defensive plays in the healthcare sector.
low - Apex has historically exhibited low volatility, with a beta below 1.0, making it attractive for risk-averse investors.